Vertical transmission of Streptococcus agalactiae can cause neonatal infections. A culture 19 test in the late stage of pregnancy is used to screen for the presence of maternal S. 20 agalactiae for intrapartum antibiotic prophylaxis. For the test, vaginal-rectal swab sampling 21 is immediately followed by enrichment culture and bacterial identification. In some cases, 22
INTRODUCTION 41
Streptococcus agalactiae (also called group B streptococcus) is vertically transmitted to the 42 newborn during delivery, and can cause neonatal infections (1, 2) . Common early-onset 43 diseases caused by this organism in infants include sepsis and pneumonia, and (rarely) 44 meningitis (1, 2) . To prevent such infections, prenatal S. agalactiae culture test is 45 recommended in the late stage of pregnancy (1, 2) . In the case of a positive test result, the 46 pregnant carrier is prophylactically treated with antibiotics to prevent vertical transmission 47 of S. agalactiae during the intrapartum period (1, 2) . 48
For the S. agalactiae culture test, the Center of Disease Control and Prevention 49 highly recommends an enrichment culture, followed by conventional S. agalactiae 50 identification (3, 4) . In the culture test, a swab is taken from the vaginal and anorectal areas, 51 and the samples are inoculated and cultured in an enrichment culture broth selective for S. 52 9 the spotted E. faecalis was examined. 126
Analysis of phage lytic activity. The phage host range was determined by a streak 127 test, as described elsewhere (12, 15) . Briefly, 200 l of overnight bacterial culture of a 128 single bacterial strain were mixed with a melted 0.5% (w/v) soft agar and plated onto 1.5% 129 (w/v) agar. Phage suspension (ca. 1.0  10 8-9 PFU/ml) was streaked onto the solidified top 130 agar. After incubation overnight at 37°C, bacterial lysis, with or without plaque formation, 131 was examined. 132
Analysis of bacterial growth inhibition by the phage mixture in S. agalactiae 133 enrichment broths. Bacteria were cultured until optical density of 0.4-0.6 at 600 nm. After 134 washing and diluting with GBwSM, 3.0-5.0  10 8 CFU/ml bacterial suspension was 135 prepared in GBwSM. Each phage suspension was diluted in THB to ca. 3.0  10 8 PFU/ml, 136 3.0  10 6 PFU/ml, and 3.0  10 4 PFU/ml. Phage mixtures were prepared by mixing equal 137 volumes of phage suspensions at the same dilution. Then, 5 l of bacterial suspension and 5 138 l of phage mixture were added to 140 l of GBwSM in a well of a flat-bottomed 139 polystyrene 96-well plate (AS ONE Co., Osaka, Japan). In the experiments, 5 l of THB 140 was used instead of the bacterial suspension and/or phage mixture as a control. The 96-well 141 plate was incubated at 37°C and sample turbidity was measured over time at 595 nm, using 142 10 a Multiskan JX spectrophotometer (Thermo Labsystems, Stockholm, Sweden). The 143 experiments were conducted in triplicate, and the growth curves were then plotted using 144 averaged values with standard deviations. 145
Analysis of bacterial densities in S. agalactiae and E. faecalis co-culture with 146 phage mixtures. Rifampicin-resistant mutant clone of S. agalactiae was isolated by 147 aerobically culturing S. agalactiae strain KUGBS2 on TSA containing 20 g/ml rifampicin 148 at 37°C for 2 d. The putative mutant clones were re-purified at least three times; each 149 re-purification round was repeated for 1 d under the same incubation conditions. One 150 resultant rifampicin-resistant mutant clone of strain KUGBS2 was obtained and was 151 tentatively designated as strain KUGBS2rif. S. agalactiae strain KUGBS2rif and E. 152 faecalis strain KUEF08 were cultured individually until optical density of 0.4-0.6 at 600 153 nm. After diluting with the enrichment broth, suspensions of 3.0  10 4 CFU/ml S. 154 agalactiae strain KUGBS2rif and 3.0  10 7 CFU/ml E. faecalis strain KUEF08 were 155 prepared. Each phage suspension was diluted with THB to ca. 3.0  10 6 PFU/ml or 3.0  156 10 4 PFU/ml. By mixing equal volumes of phage suspensions at the same dilution, mixtures 157 of two different dilutions of phages were prepared. 158
For the experiment, 100 l each of S. agalactiae strain KUGBS2rif and E. faecalis 159 11 strain KUEF08, and 300 l of phage mixture were added to 10 ml of the S. agalactiae 160 enrichment broth. As negative controls, the same volume of THB was added instead of 161 bacterial suspensions and/or phage suspensions. The mixtures were microaerobically 162 incubated at 37°C for 24 h. Total bacterial density, and S. agalactiae strain KUGBS2rif and 163 E. faecalis strain KUEF08 densities were determined. Total bacterial densities were 164 determined on TSA. TSA supplemented with 20 g/ml rifampicin and 165
Enterococcus-selective agar (EF agar base "Nissui"; Nissui Pharmaceutical Co., Tokyo, 166 Japan) were used to determine the densities of S. agalactiae strain KUGBS2rif and E. 167 faecalis strain KUEF08, respectively. S. agalactiae strain KUGBS2rif did not grow on the 168 Enterococcus-selective agar; conversely, E. faecalis strain KUEF08 did not grow on TSA 169 containing 20 g/ml rifampicin. Student's t-tests were used to analyze differences between bacterial densities in different 190 treatments. The value of P < 0.01 was considered to indicate statistically significant 191 difference. 192
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RESULTS AND DISCUSSION 201
Phage characteristics. Phages phiEF24C, phiEF17H, and phiM1EF22 were used 202 in the current study. Phage phiEF24C, one of the well-studied Enterococcus phages, is 203 classified into the family Myoviridae subfamily Spounavirinae (26). Based on the 204 whole-genome sequence similarities to the phage phiEF24C genome, phages phiEF17H 205 and phiM1EF22 share viral taxonomy with that phage (Table S3 ). Phages sharing this 206 particular viral taxonomy are highly virulent toward host bacteria (27). 207 MLST analysis of the E. faecalis vaginal swab isolates ( Fig. 1) show antibacterial activity (e.g., bacteriocin production) to the S. agalactiae, while some of 212 them are able to show anti-bacterial activity to a variety of bacteria (5, 28) . Testing the 213 antibacterial activity to S. agalactiae strains by the spot-on-lawn assay, no anti-S. 214
agalactiae activity was observed among these E. faecalis strains. 215
Phage lytic activity was examined by a streak test using these E. faecalis strains 216 ( Fig. 1 ). Phages phiEF24C, phiEF17H, and phiM1EF22 showed lytic activity toward 217 63.3% (19/30), 76.7% (23/30), and 66.7% (20/30), respectively, of the tested E. faecalis 218 strains. Lytic activities of the three phages with other bacterial vaginal swab isolates (E. 219 avium, E. faecium, and S. agalactiae strains) were also examined, but no lytic activity was 220 observed. 221
Lytic activity of the phage mixture as an E. faecalis-selective antimicrobial 222 agent. Phages phiEF24C, phiEF17H, and phiM1EF22 lysed different E. faecalis strains and 223 also some common strains. Theoretically, a combination of these three phages lysed a 224 broader range of E. faecalis strains than any single phage tested. Phage mixture containing 225 the three phages was prepared by mixing phage particles in 1:1:1 ratio. The lytic spectrum 226 of the phage mixture was then examined by using a streak test. The phage mixture showed 227 15 lytic activity toward 86.7% (26/30) of E. faecalis strains tested (Fig. 1) . Four E. faecalis 228 strains were not lysed by the phages, namely, KUEF02 (MLST ST47), KUEF18 (ST64), 229 KUEF15 (ST30), and KUEF28 (ST179). The phage mixture did not show any lytic activity 230 with the other tested bacteria, i.e., E. avium, E. faecium, and S. agalactiae. 231
To evaluate the effect of the phage mixture on the growth of E. faecalis in the 232 enrichment broth, E. faecalis growth was monitored in the presence of three dilutions of the 233 phage mixture in GBwSM. The medium lacked the customary pigment enhancer 234 methotrexate to improve data reliability (16, 17) . After bacterial inoculation, phage mixture 235 was added to the multiplicity of infection (MOI) of each phage of 1, 10 -2 , or 10 -4 . For the S. 236 agalactiae enrichment culture, 18-24-h incubation is recommended (3, 4) . Consequently, 237 the turbidity of cultures of 30 E. faecalis strains described in Fig. 1 was recorded in the 238 presence or absence of the phage mixture over 24 h. 239
To simplify data interpretation, E. faecalis growth curves were tentatively 240 categorized into four patterns (A-D), after comparing with the growth curve of untreated E. 241 faecalis ( Fig. 2A) . For strains representing pattern A growth curve, E. faecalis growth was 242 inhibited throughout the experiment. For strains representing pattern B growth curve, E. 243 faecalis growth was initially inhibited (8 h post inoculation) and then gradually recovered. 244
For strains representing pattern C growth curve, bacteria showed an initial growth but were 245 then lysed. Pattern C was a typical phage lysis pattern at the lower MOI tested. E. faecalis 246 strains that exhibited growth patterns A-C were inhibited by the phage treatment. The 247 tested E. faecalis strains treated with higher concentrations of phage mixtures and ones that 248 were most sensitive to phage mixture treatments tended to exhibit growth patterns A, B, 249 and C, in the order of strongest to weakest inhibition. On the other hand, phage treatment 250 did not inhibit E. faecalis strains exhibiting growth pattern D. The four phage-insensitive E. 251 faecalis strains (KUEF02, KUEF18, KUEF15, and KUEF28), and E. avium, E. faecium, 252 and S. agalactiae strains exhibited growth pattern D. The reasons for such tentative growth 253 pattern categorization (i.e., growth patterns A-D) were probably due to (1) different 254 sensitivity of E. faecalis strains to phages, and (2) the use of three dilutions of the phage 255 mixture in experiments. 256
The tentative grouping of growth patterns of the 30 tested E. faecalis is 257 summarized in Fig. 2B . Phage mixture treatments at the highest and the second highest 258 phage density (i.e., MOI 1 and 10 -2 , respectively) inhibited the growth of 86.7% (26/30) of 259 E. faecalis strains, which was in agreement with the results of the streak test (Fig. 1) . On 260 the other hand, when the phage density was reduced (i.e., MOI 10 -4 ), the number of E. 261 faecalis strains whose growth was inhibited was reduced (76.7%, 23/30 strains). The latter 262 23 strains largely represented growth pattern C, probably because the input phage titer was 263 much lower than that in the other phage mixture treatments. The seven remaining E. 264 faecalis strains that exhibited growth pattern D included the four phage mixture-insensitive 265 strains mentioned above and strains KUEF03 (ST3), KUEF19 (ST16), and KUEF30 (ST16). 266
In the current study, a correlation between growth patterns and STs was not observed 267 among the E. faecalis strains tested. 268
Based on these observations, we concluded that the phage mixture inhibited the 269 growth of 86.7% (26/30) of E. faecalis strains tested, when used at sufficiently high density 270 (i.e., MOI of at least 10 -2 ). 271
The effect of phage mixture on S. agalactiae and E. faecalis cell densities in 272 experimental enrichment cultures. Phage mixture may have been contaminated with this 273 anti-S. agalactiae agents during phage mixture preparation (i.e., during phage propagation 274 on the E. faecalis host). However, incubation of phage mixture with S. agalactiae did not 275 significantly affect bacterial viability, compared with a THB-treated negative control (Fig.  276   S1) , excluding the possibility of phage mixture contamination with anti-S. agalactiae 277 substances. 278
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The effects of phage mixture were then examined in co-cultures of E. faecalis and 279 S. agalactiae in the Granada-type enrichment broth. The rifampicin-resistant mutant clone 280 of strain KUGBS2, KUGBS2rif, was isolated. S. agalactiae strain KUGBS2rif and E. 281 faecalis strain KUEF08 were used to quantify viable bacterial individually. To mimic the 282 situation that S. agalctaie was poorly recovered, S. agalactiae strain KUGBS2rif and E. 283 faecalis strain KUEF08 were inoculated into GBwSM at 3.0  10 2 CFU/ml and 3.0  10 5 284 CFU/ml, respectively. Either of the two dilutions of phage mixture (at MOI of each phage 285 of 10 -1 and 10 -3 to E. faecalis) were added. As a negative control, THB was used instead of 286 the phage mixture. 287
Changes in bacterial cell density (total bacteria, S. agalactiae, and E. faecalis) 288 were then monitored over time (Fig. 3) . Based on the determined total bacteria numbers, 289 bacteria grew exponentially for up to 12 h, following which the cultures entered the 290 stationary phase of growth. Hence, 12-24-h incubation was sufficient to achieve bacterial 291 enrichment in that particular experimental setting. Moreover, changes in E. faecalis and S. 292 agalactiae cell densities were then evaluated. In the negative control group (i.e., no phage 293 treatment), E. faecalis grew much better than S. agalactiae. In the phage treatment groups, 294 the opposite was observed. After 12 and 24 h, in the phage treatment groups, cell density of 295 19 E. faecalis was significantly lower than that of S. agalactiae (P < 0.01). 296
Several types of enrichment broths are commercially available for S. agalactiae 297 culture test. In addition to the GBwSM medium, we also evaluated the effectiveness of 298 phage treatment of an E. faecalis and S. agalactiae co-culture in the commercially available 299 pigmented enrichment Lim broth (Fig. S2) . The experiments were performed as described 300 above. Inhibition of E. faecalis growth, compared with the untreated group, was observed 301 in phage treatment groups at both MOIs of each phage tested (i.e., 1 and 10 -2 ) (Fig. S3) . 302
This indicated that phage mixture inhibited E. faecalis growth and facilitated S. agalactiae 303 growth in both S. agalactiae enrichment broths. 304
Efficient detection of S. agalactiae after enrichment culturing in the presence 305 of phage mixture. In the S. agalactiae culture test, bacteria are generally identified in a 306 culture aliquot after enrichment culture. Consequently, we then evaluated the efficiency of 307 S. agalactiae identification after the experimental enrichment culture. As the identification 308 assay, we used growth on the S. agalactiae chromogenic agar, in which S. agalactiae 309 colonies are distinguished from E. faecalis colonies based on color. We tested several S. 310
agalactiae-E. faecalis combinations. E. faecalis and S. agalactiae strains were first 311 inoculated at 100:1 ratio in the Granada-type enrichment broth, the phage mixture was 312 20 added (at an MOI of each phage at 10 -1 to E. faecalis), and the cultures incubated. 313
Enrichment culture aliquots were plated on chromogenic agar, and the resultant colony 314 appearance evaluated (Fig. 4) . After enrichment of all phage-treated S. agalactiae-E. 315 faecalis sets, S. agalactiae colonies were dominant on the agar plates. By contrast, in 316 enrichment cultures without phage treatment, only few S. agalactiae colonies were 317 observed on the chromogenic agar, while E. faecalis colonies were dominant. The same 318 experiment was performed using the modified Lim broth and several S. agalactiae-E. 319 faecalis combinations (Fig. S4) . The data were in agreement with observations made using 320 the GBwSM medium. Thus, the phage mixture treatment improved the S. agalactiae 321 culture test by inhibiting the undesirable growth of E. faecalis, even when the initial E. 322 faecalis cell density was as high 10 5 CFU/ml. 323
Phage application potential in the clinical setting. In the current study, we 324 showed that a specific phage mixture effectively inhibited the growth of E. faecalis in an S. 325 agalactiae culture test in the experimental setting. Before reagent manufacture and clinical 326 application, phage composition in the phage mixture, the usage per assay (i.e., volume and 327 phage density), storage of the phage mixture, and production cost should be optimized. 328
As a first consideration, strains insensitive to the phage mixture may occur at a 329 21 higher than expected rate in the clinical setting. To address this issue, phage sensitivity of E. 330 faecalis strain should be constantly examined. The effective spectrum of phages in a 331 mixture can be modified by replacing and/or adding other phages, including newly-isolated 332 phages, naturally-evolved phages, and/or genetically-modified phages (29, 30) . E.g., by 333 adding six newly isolated phages to the phage mixture developed in the current study, we 334 increased the inhibition efficiency among the tested E. faecalis strains to 96.7% (29/30) 335 (data not shown). Hence, updating the composition of the phage mixture will help to 336 address the problem associated with the phage-insensitive strains. 337
Next, we considered the usage per assay. Assuming that the volume of the 338 enrichment broth is ca. 3-4 ml, a drop of phage mixture suspension (i.e., 30-50 l of a 339 solution of ca. 1.0  10 7 PFU/ml of each phage) would suffice for an assay. Such usage per 340 assay is in line with the usage of phage mixture in experiments performed in the current 341 study (Fig. 4) . Thus, phage mixture complies with the usage expected in a clinical setting. 342
Moreover, the quality of the phage mixture should be guaranteed to allow its 343 commercialization. Phages are generally stable at 4°C in culture media for a certain period 344 of time (31, 32), which suggests that phage products can be distributed on a market-scale 345 using the cold chain. Accordingly, we examined the infectious density of each phage 346 22 solution during storage at 4°C for 270 d, and we did not observe any substantial reduction 347 in phage particle density during this time period (Fig. S5) . Shelf life of culture medium is 348 generally up to 6 months (33), and no loss in sensitivity in S. agalactiae enrichment broths 349 were observed after at least 4 months (34). Thus, the stability of the phage mixture 350 appeared to be in line with the storage of the enrichment broths. 351
Finally, the use of phage mixture should be cost-effective. Phage production on a 352 bioreactor-scale has been recently investigated because of increased interest in phage 353 therapy. Consequently, the cost of phage production is estimated to be $4.4  10 −13 /phage 354 particle (35) (36) (37) . Hence, the calculated cost of phage mixture per assay in the current study 355 is only $2.2  10 −7 ($4.4  10 −13 /phage particle multiplied by the number of phage particles 356 in the mixture, i.e., 1.0  10 7 PFU/ml  50 l). Several commercial phage companies have 357 been founded worldwide (38). Thus, phage mixture may, in theory, be produced for the S. 358 agalactiae culture test in a cost-effective manner. 359
After commercialization of the phage mixture, special attention should be devoted 360 to the biological characteristics of phages to avoid laboratory accidents, since phage 361 products are not commonly used in the clinical microbiology. Phages multiply 362 exponentially and exceed bacterial growth, which might lead to phage contamination and 363 23 interference with E. faecalis culture tests in a clinical laboratory. To avoid such accidents, 364 appropriate safety precautions should be instated when preparing to use phage products. 365
These can include change of gloves after usage, aseptic handling at a specified bench, and 366 storage in a specific cabinet (39). We believe that that the phage mixture satisfies the usage 367 in terms of application volume and density, as long as the knowledge and safety precautions 368 for phage products are disseminated and implemented. 369
Considering the above, we anticipate that the phage mixture will become 370 commercially available for S. agalactiae enrichment broths in the future and will be used in 371 the clinical setting. 372
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